Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 25,846 | 29,128 | 10,489 | 9,364 | 6,397 |
| TOTAL | $26,400 | $29,661 | $10,687 | $9,517 | $6,501 |
| Non-Current Assets | |||||
| PPE Net | N/A | 1 | 3 | 8 | 6 |
| Intangibles | 8 | 15 | 23 | 30 | 36 |
| Other Non-Current Assets | 0 | 0 | 0 | 6 | 69 |
| TOTAL | $8 | $16 | $26 | $44 | $111 |
| Total Assets | $26,408 | $29,677 | $10,713 | $9,561 | $6,612 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 448 | 906 | 762 | 397 | 384 |
| Accrued Expenses | 845 | 729 | 1,651 | 1,161 | 1,551 |
| TOTAL | $1,360 | $1,703 | $2,486 | $1,638 | $2,215 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | N/A | N/A | N/A | 200 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 6 | 0 |
| TOTAL | $N/A | $N/A | $N/A | $6 | $N/A |
| Total Liabilities | $1,360 | $1,703 | $2,486 | $1,644 | $2,215 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 28,825 | 23,546 | 21,933 | N/A | N/A |
| Common Shares | 28 | 22 | 18 | 16 | 13 |
| Retained earnings | -140,049 | -118,925 | -101,965 | -80,018 | -69,137 |
| Other shareholders' equity | 7,565 | 7,346 | 7,333 | 7,384 | 7,154 |
| TOTAL | $25,048 | $27,974 | $8,227 | $7,917 | $4,397 |
| Total Liabilities And Equity | $26,408 | $29,677 | $10,713 | $9,561 | $6,612 |